Enhertu (trastuzumab deruxtecan) has demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (DFS) compared to trastuzumab (Herceptin) in patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant therapy. This data comes from the DESTINY-Breast05 phase 3 trial, marking a significant advancement in the treatment of this aggressive form of cancer.

The trial’s findings, presented at a major medical conference and published in a peer-reviewed journal, indicate that Enhertu significantly reduces the risk of disease recurrence or death in this patient population. Specifically, the study evaluated patients who did not achieve a pathological complete response (pCR) following neoadjuvant chemotherapy and HER2-targeted therapy.

Key Trial Details

DESTINY-Breast05 enrolled a diverse group of patients with HER2-positive early breast cancer. Participants were randomized to receive either Enhertu or trastuzumab, both administered intravenously. The primary endpoint was invasive DFS, defined as the time from randomization to the first occurrence of invasive recurrence or death from any cause.

Secondary endpoints included overall survival (OS), distant disease-free survival (DDFS), and safety. The trial was designed to assess the efficacy and safety of Enhertu in the adjuvant setting, following the completion of neoadjuvant therapy.

The results showed a substantial improvement in invasive DFS in the Enhertu arm compared to the trastuzumab arm, with a hazard ratio (HR) that favored Enhertu. This suggests that Enhertu is more effective at preventing cancer recurrence and improving patient outcomes. The safety profile of Enhertu in DESTINY-Breast05 was consistent with previous trials, although certain adverse events, such as interstitial lung disease (ILD), require careful monitoring and management.

Implications for Treatment

These findings have the potential to change the standard of care for patients with HER2-positive breast cancer who have residual disease after neoadjuvant therapy. Enhertu could become a new standard adjuvant treatment option, offering improved outcomes and potentially extending survival for these patients. Clinicians may now consider Enhertu for patients who have not achieved a pCR after neoadjuvant treatment.

Further analysis of the DESTINY-Breast05 data is ongoing, including assessments of overall survival and long-term safety. These additional analyses will provide a more complete picture of the benefits and risks associated with Enhertu treatment in this setting.

The medical community welcomes these results as they represent an important step forward in the fight against HER2-positive breast cancer. Future research will focus on identifying biomarkers that can help predict which patients are most likely to benefit from Enhertu, as well as exploring strategies to minimize the risk of adverse events.

The DESTINY-Breast05 trial underscores the importance of ongoing research and innovation in cancer treatment, offering hope for improved outcomes and enhanced quality of life for patients battling this disease.

Image Source: Google | Image Credit: Respective Owner